Upstream Bio reports a 56% reduction in severe-asthma exacerbations in the Phase 2 VALIANT trial of verekitug.
#Asthma #Biotech #Biotechnology #HealthInnovation
Disclaimer: This is NOT a financial advice
Upstream Bio reports a 56% reduction in severe-asthma exacerbations in the Phase 2 VALIANT trial of verekitug. #Asthma #Biotech #Biotechnology #HealthInnovation Disclaimer: This is NOT a financial advice
0 views
Published on 15/09/2026 06:47
0:13
Upstream Bio reports a 56% reduction in severe-asthma exacerbations in the Phase 2 VALIANT trial of verekitug.
#Asthma #Biotech #Biotechnology #HealthInnovation
Disclaimer: This is NOT a financial advice
0 comments
?